Tenapanor

Last Updated: 06/30/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 170 publications

Constipation with bloating: a clinical approach to evaluation and management.

Constipation with bloating: a clinical approach to evaluation and management.

Journal: Annals of medicine

Published: June 19, 2026

How are developments in the treatment armamentarium of hyperphosphatemia addressing the current therapeutic challenges?

How are developments in the treatment armamentarium of hyperphosphatemia addressing the current therapeutic challenges?

Journal: Expert opinion on pharmacotherapy

Published: June 10, 2026

Correction to: Long-Term Safety of Tenapanor in Patients With Irritable Bowel Syndrome With Constipation in the T3MPO-3 Study.

Correction to: Long-Term Safety of Tenapanor in Patients With Irritable Bowel Syndrome With Constipation in the T3MPO-3 Study.

Journal: Neurogastroenterology and motility

Published: June 08, 2026

Novel therapeutic approaches for phosphate regulation.

Novel therapeutic approaches for phosphate regulation.

Journal: Current opinion in nephrology and hypertension

Published: May 14, 2026

Correction to: Abdominal Symptom Improvement During Clinical Trials of Tenapanor in Patients With Irritable Bowel Syndrome With Constipation: A Post Hoc Analysis.

Correction to: Abdominal Symptom Improvement During Clinical Trials of Tenapanor in Patients With Irritable Bowel Syndrome With Constipation: A Post Hoc Analysis.

Journal: The American journal of gastroenterology

Published: May 04, 2026

Correction to: Safety and Efficacy of Tenapanor for Long-term Serum Phosphate Control in Maintenance Dialysis: A 52-Week Randomized Phase 3 Trial (PHREEDOM).

Correction to: Safety and Efficacy of Tenapanor for Long-term Serum Phosphate Control in Maintenance Dialysis: A 52-Week Randomized Phase 3 Trial (PHREEDOM).

Journal: Kidney360

Published: April 30, 2026

Correction to: Tenapanor as Therapy for Hyperphosphatemia in Maintenance Dialysis Patients: Results from the OPTIMIZE Study.

Correction to: Tenapanor as Therapy for Hyperphosphatemia in Maintenance Dialysis Patients: Results from the OPTIMIZE Study.

Journal: Kidney360

Published: April 17, 2026

Tenapanor-Associated Bowel Effects in Hemodialysis: Persistence Barriers and Practical Continuation Strategies.

Tenapanor-Associated Bowel Effects in Hemodialysis: Persistence Barriers and Practical Continuation Strategies.

Journal: Hemodialysis international. International Symposium on Home Hemodialysis

Published: April 14, 2026

Role of Na+/H+ exchanger 3 in acidification and morphological remodeling of tubulovesicles in gastric parietal cells.

Role of Na+/H+ exchanger 3 in acidification and morphological remodeling of tubulovesicles in gastric parietal cells.

Journal: American journal of physiology. Cell physiology

Published: April 10, 2026

Analysis of Phosphate Transporters in Peritoneal Cells and Tissues and Their Transport Kinetics In Vitro.

Analysis of Phosphate Transporters in Peritoneal Cells and Tissues and Their Transport Kinetics In Vitro.

Journal: International journal of molecular sciences

Published: March 06, 2026

Treatment Satisfaction with Tenapanor: Real-World Survey of Patients with End-Stage Renal Disease and Hyperphosphatemia.

Treatment Satisfaction with Tenapanor: Real-World Survey of Patients with End-Stage Renal Disease and Hyperphosphatemia.

Journal: Patient preference and adherence

Published: March 05, 2026

Tenapanor Beyond Phosphate: Gut Sodium Transport, Stool Transit, and Volume Balance in Dialysis.

Tenapanor Beyond Phosphate: Gut Sodium Transport, Stool Transit, and Volume Balance in Dialysis.

Journal: Hemodialysis international. International Symposium on Home Hemodialysis

Published: February 23, 2026

Showing 1-12 of 170

Last Updated: 06/30/2026